Why the study?
Does oxamate act as a clinically useful differential inhibitor of lactate dehydrogenase isoenzymes for diagnosing myocardial infarction?
Does oxamate act as a clinically useful differential inhibitor of lactate dehydrogenase isoenzymes for diagnosing myocardial infarction?
Oxamate is not a clinically useful differential inhibitor of lactate dehydrogenase isoenzymes for distinguishing myocardial infarction from liver disease.
Oxamate lacks diagnostic utility for MI in patient sera; leaves open whether refined LDH inhibitors merit further development.
Oxamate is a non-competitive inhibitor of various lactate dehydrogenase preparations of human and animal origin when lactate is used as substrate. Its action on LD(1) (H(4)) is greater than that on LD(5) (M(4)), an effect which is most marked at a concentration about 3 mmol/1. Under these conditions the enzyme activity of a human heart extract is inhibited by about 50% while that of a human liver extract is reduced by only about 20%. The lactate dehydrogenase activities of a series of normal and pathological sera were determined in the presence or absence of oxamate. Those from patients with myocardial infarction were more sensitive to oxamate inhibition than those from patients with liver disease, but the differences observed were insufficiently great to warrant the use of oxamate as a differential inhibitor for clinical purposes.
No takes yet. Share an insight, caveat, or question.
Wilkinson et al. (1972) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: